S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:TMDX

TransMedics Group (TMDX) Stock Forecast, Price & News

$56.77
-0.14 (-0.25%)
(As of 09/28/2023 ET)
Compare
Today's Range
$56.71
$58.59
50-Day Range
$53.47
$93.88
52-Week Range
$38.86
$99.63
Volume
671,210 shs
Average Volume
590,255 shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$85.00

TransMedics Group MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
49.7% Upside
$85.00 Price Target
Short Interest
Bearish
14.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of TransMedics Group in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.75 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.51) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

555th out of 969 stocks

Electromedical Equipment Industry

14th out of 20 stocks


TMDX stock logo

About TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TMDX Price History

TMDX Stock News Headlines

3 Best Stocks to Buy With $300 Right Now
Checking In on the Fed, FedEx, and TransMedics
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
TransMedics Group (NASDAQ: TMDX)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
TransMedics Completes Acquisition of Summit Aviation
Why Shares of TransMedics Group Are Falling Friday
Bridge to Life Divests Certain Assets to TransMedics
See More Headlines
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Company Calendar

Last Earnings
8/03/2023
Today
9/28/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMDX
Fax
N/A
Employees
212
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$85.00
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$74.00
Forecasted Upside/Downside
+48.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-36,230,000.00
Pretax Margin
-11.72%

Debt

Sales & Book Value

Annual Sales
$93.46 million
Book Value
$5.87 per share

Miscellaneous

Free Float
30,416,000
Market Cap
$1.87 billion
Optionable
Not Optionable
Beta
1.52
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Waleed H. Hassanein M.D.Dr. Waleed H. Hassanein M.D. (Age 55)
    Founder, Pres, CEO & Director
    Comp: $1.46M
  • Mr. Stephen GordonMr. Stephen Gordon (Age 55)
    CFO, Treasurer & Sec.
    Comp: $744.62k
  • Dr. Tamer I. Khayal M.D. (Age 54)
    Chief Commercial Officer
    Comp: $748.78k
  • Ms. Miriam C. Provost Ph.D. (Age 62)
    VP of Global Regulatory Affairs
    Comp: $535.93k
  • Mr. Nick Corcoran (Age 41)
    Sr. VP of Supply Chain & Operations
  • Mr. Mark Anderson
    Sr. Director of Technology Devel.
  • Mr. Anil Ranganath
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Susan Goodman
    VP of HR













TMDX Stock - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMDX shares.
View TMDX analyst ratings
or view top-rated stocks.

What is TransMedics Group's stock price forecast for 2023?

8 brokerages have issued 1 year price targets for TransMedics Group's stock. Their TMDX share price forecasts range from $74.00 to $110.00. On average, they predict the company's share price to reach $85.00 in the next twelve months. This suggests a possible upside of 48.2% from the stock's current price.
View analysts price targets for TMDX
or view top-rated stocks among Wall Street analysts.

How have TMDX shares performed in 2023?

TransMedics Group's stock was trading at $61.72 at the beginning of the year. Since then, TMDX shares have decreased by 7.1% and is now trading at $57.36.
View the best growth stocks for 2023 here
.

When is TransMedics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our TMDX earnings forecast
.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) issued its earnings results on Thursday, August, 3rd. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.12. The company earned $42.46 million during the quarter, compared to the consensus estimate of $42.42 million. TransMedics Group had a negative net margin of 11.77% and a negative trailing twelve-month return on equity of 9.98%. The firm's revenue was up 136.9% on a year-over-year basis. During the same period last year, the business posted ($0.41) earnings per share.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $180.00 million-$190.00 million, compared to the consensus revenue estimate of $173.91 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.08%), Allspring Global Investments Holdings LLC (3.98%), Driehaus Capital Management LLC (3.56%), Sandhill Capital Partners LLC (2.50%), Credit Suisse AG (2.41%) and State Street Corp (2.39%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends
.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $57.36.

How much money does TransMedics Group make?

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $1.87 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does TransMedics Group have?

The company employs 212 workers across the globe.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.

This page (NASDAQ:TMDX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -